Prokarium

Prokarium is a clinical-stage biopharmaceutical company developing microbial immunotherapies using engineered Salmonella strains.

Its platform combines synthetic biology with AI-enabled discovery to create programmable bacterial therapeutics that deliver payloads within the tumour microenvironment.

The lead programme targets non-muscle invasive bladder cancer and is in Phase 1 clinical trials in the US. The company also has earlier-stage oral vaccine programmes based on thermostable microbial delivery technology.